• Meropenem trihydrate in Resistance Workflows

  2026-09-17

  Use Meropenem trihydrate as a controlled antibacterial perturbation for MIC testing, resistance phenotyping, and metabolomics-informed assay design. This workflow connects rapid LC-MS/MS signatures with practical experiments in gram-negative bacterial infections and translational infection models.

• BML-277 for Reproducible Chk2 Assays

  2026-09-16

  Learn how BML-277, SKU B1236, can support controlled Chk2 inhibition in biochemical, viability, and radiation-response workflows. This scenario-based guide connects product specifications with practical assay design, interpretation, storage, and supplier-selection decisions.

• Dual-Mode mRNA Readouts for Translation and Delivery

  2026-09-16

  Translational mRNA research increasingly requires two answers from one experiment: where the RNA goes and whether it produces functional protein. This thought-leadership article examines how Cap1 capping, 5-moUTP modification, Cy5 labeling, and Firefly Luciferase reporting can support that decision framework, while using the vorinostat lipoplex study to clarify what delivery and expression data can—and cannot—prove.

• Meropenem: From PBP Action to Resistance Mapping

  2026-09-15

  Meropenem is a β-lactam antibiotic carbapenem whose value in research extends beyond susceptibility testing. This article connects PBP pharmacology with plasmid transmission, helping researchers design more interpretable assays for carbapenem-resistant bacterial infections and Gram-negative infection models.

• Aurora A in Retinoblastoma: Evidence for Targeted Therapy

  2026-09-15

  A 2024 American Journal of Pathology study identifies AURKA overexpression as a recurrent feature of human retinoblastoma and links it to histopathologic indicators of high-risk disease. By combining patient-tissue analysis with genetic and pharmacologic perturbation in cellular, patient-derived, and xenograft models, the work supports AURKA as a candidate vulnerability while defining its relationship with MYCN.

• tFUS Suppresses Stroke Neuroinflammation via SHP2

  2026-09-14

  This study identifies the Nespas/miR-383-3p/SHP2 axis as a mechanistic link between low-intensity transcranial focused ultrasound stimulation and suppression of NLRP3-mediated neuroinflammation after ischemic stroke. Rat and BV2 microglial experiments connect tFUS treatment with improved neurological outcomes, reduced infarction, and lower inflammasome activation, while also defining experimental entry points for studying SHP2-dependent microglial responses.

• Meropenem: Mechanism to Resistance Strategy

  2026-09-14

  A translational perspective on Meropenem that connects PBP-targeted bactericidal activity with carbapenemase mobility, resistance-aware assay design, and strategic use in Gram-negative infection models.

• JNK-IN-7: Causal Mapping of Infection Apoptosis

  2026-09-13

  JNK-IN-7 is a selective JNK inhibitor for dissecting c-Jun signaling, pathogen-induced apoptosis, and innate immune responses. This article presents a phase-resolved assay strategy that separates MAPK pathway activity from downstream cell-death execution.

• Ertapenem Sodium Salt in Resistance Workflows

  2026-09-12

  Build a practical Ertapenem sodium salt workflow that links broth microdilution with carbapenemase detection, plasmid localization, and transfer analysis. The approach converts a broad-spectrum phenotype into evidence for antibiotic resistance research while clearly separating assay observations from clinical interpretation.

• Protease and Phosphatase Inhibitor Cocktail Workflow

  2026-09-11

  Protect protein abundance and phosphorylation states from the moment cells or tissues are disrupted. This EDTA-free, 100X formulation is especially useful for metal-sensitive signaling assays, phosphoprotein immunoblotting, organoid studies, and comparative proteomics.

• Cefoperazone Sodium Salt: Assay Logic

  2026-09-10

  Cefoperazone sodium salt is a β-lactam research tool for studying antibacterial activity, enzyme stability, and biliary tract infection models. This guide goes beyond compound description to show how comparator data, assay design, and formulation choices shape defensible experimental conclusions.

• PTT and CD47 Blockade in Oral Cancer

  2026-09-10

  A 2026 study shows that photothermal therapy (PTT) can strengthen CD47 blockade in oral squamous cell carcinoma by coupling calreticulin-dependent phagocytic signaling with extracellular matrix remodeling. The findings clarify why blocking a tumor cell “don’t eat me” signal may be insufficient without both an “eat me” cue and improved macrophage access.

• NAD+ Workflows for AMPK Energy-Stress Assays

  2026-09-09

  Build reproducible NAD+ assays that separate redox chemistry, enzyme activity, and autophagy signaling during energy stress. This workflow translates new AMPK–ULK1 findings into practical controls for metabolic, deacetylation, and inhibitor-design experiments.

• MK-4827: Functional PARP Sensitization Beyond BRCA

  2026-09-09

  MK-4827 (Niraparib) is a selective PARP-1/-2 inhibitor for dissecting DNA repair dependence in cancer research. This article develops a functional assay framework showing how BRCA2 protein state, hyperthermia, and orthogonal readouts can reveal PARP inhibitor sensitivity beyond fixed BRCA genotype.

• Baicalin Methyl Ester and Intestinal Barrier Repair

  2026-09-08

  A 2024 Biomedicine & Pharmacotherapy study shows that baicalin methyl ester attenuates LPS-induced intestinal barrier injury in mice and MODE-K epithelial cells. Its central contribution is the integration of P65 binding evidence with TNF-α, MLCK, and tight-junction measurements, linking inflammatory signaling to barrier restoration.

7962 records 1/531 page Next 12345 下5页 Last page